SeaLife secures funding for development of new active substance in Biocide/MedTech field


SeaLife secures fresh funding from a basic grant of The Austrian Research Promotion Agency (FFG) in May 2015. The fund supports the development of SeaLife’s polymeric agent SLP0901 to enter the market as new active substance in the Biocide/MedTech field. SeaLife`s antimicrobial polymeric compound which is highly active against Gram+/Gram- pathogens and fungi has its source in observing coral defense strategies. The compound stands out by its excellent nebulization capabilities (cold/dry nebulization) and the reduction and/or destruction of all kind of pathogens.

< back